PURPOSE: Transglutaminase 2 (TGase 2), a cross-linking enzyme, plays an important role in both pro-survival and anti-apoptosis during oncogenesis. For instance, TGase 2 induces NF-κB activation through I-κBα polymerization, which leads to the increase of pro-survival factors such as BCl-2. TGase 2 also suppresses apoptosis via depletion of caspase 3 and cathepsin D. Therefore, a specific TGase 2 inhibitor may become a very useful treatment for cancer showing high levels of TGase 2 expression. METHODS: By small-molecule library screening, we managed to locate a competitive TGase 2 inhibiting quinoxaline compound (GK13) from 50 other quinoxaline derivatives. The 50 compounds that were screened represent a thousand structurally diverse, potentially pharmaceutical heterocyclic compound libraries, including benzopyrans, oxadiazoles, thiadiazoles, and quinoxalines. By measuring GI50, TGI, and LC50 using SRB assay, GK13 was selected. RESULTS: In vitro enzyme kinetics using guinea pig liver TGase 2 showed that IC50 value was about 16.4 E-6 M. GK13 inhibits TGase 2-mediated I-κBα polymerization in a dose-dependent manner. LC50 of GK13 showed greater efficacy as 4.3E-4 M than LC50 of doxorubicin that showed efficacy as 3.87E-3 M in NCC72 composing 11 tissue origins and 72 cancer cell lines. CONCLUSION: GK13 showed a possibility that quinoxaline derivatives may be effective for anti-cancer activity via TGase 2 inhibition.
PURPOSE:Transglutaminase 2 (TGase 2), a cross-linking enzyme, plays an important role in both pro-survival and anti-apoptosis during oncogenesis. For instance, TGase 2 induces NF-κB activation through I-κBα polymerization, which leads to the increase of pro-survival factors such as BCl-2. TGase 2 also suppresses apoptosis via depletion of caspase 3 and cathepsin D. Therefore, a specific TGase 2 inhibitor may become a very useful treatment for cancer showing high levels of TGase 2 expression. METHODS: By small-molecule library screening, we managed to locate a competitive TGase 2 inhibiting quinoxaline compound (GK13) from 50 other quinoxaline derivatives. The 50 compounds that were screened represent a thousand structurally diverse, potentially pharmaceutical heterocyclic compound libraries, including benzopyrans, oxadiazoles, thiadiazoles, and quinoxalines. By measuring GI50, TGI, and LC50 using SRB assay, GK13 was selected. RESULTS: In vitro enzyme kinetics using guinea pig liver TGase 2 showed that IC50 value was about 16.4 E-6 M. GK13 inhibits TGase 2-mediated I-κBα polymerization in a dose-dependent manner. LC50 of GK13 showed greater efficacy as 4.3E-4 M than LC50 of doxorubicin that showed efficacy as 3.87E-3 M in NCC72 composing 11 tissue origins and 72 cancer cell lines. CONCLUSION: GK13 showed a possibility that quinoxaline derivatives may be effective for anti-cancer activity via TGase 2 inhibition.
Authors: Kihang Choi; Matthew Siegel; Justin L Piper; Liya Yuan; Eun Cho; Pavel Strnad; Bishr Omary; Keith M Rich; Chaitan Khosla Journal: Chem Biol Date: 2005-04
Authors: Jacqueline Soto-Sánchez; Luis A Caro-Gómez; Alma D Paz-González; Laurence A Marchat; Gildardo Rivera; Rosa Moo-Puc; Diego G Arias; Esther Ramírez-Moreno Journal: Parasitol Res Date: 2020-01-06 Impact factor: 2.289
Authors: Nahed N E El-Sayed; Taghreed M Al-Otaibi; Mona Alonazi; Vijay H Masand; Assem Barakat; Zainab M Almarhoon; Abir Ben Bacha Journal: Molecules Date: 2021-05-23 Impact factor: 4.927
Authors: Hyun Jung Byun; Kyung Jin Kang; Mi Kyung Park; Hye Ja Lee; June Hee Kang; Eun Ji Lee; You Ri Kim; Hyun Ji Kim; Young Woo Kim; Kyung Chae Jung; Soo Youl Kim; Chang Hoon Lee Journal: Biomol Ther (Seoul) Date: 2013-09-30 Impact factor: 4.634